Cargando…

Implication of problematic substance use in poststroke depression: an hospital-based study

The prevalence of clinically defined problematic substance use among stroke patients is overlooked and its association with post-stroke depression (PSD) is unknown. Our aims were to: (1) estimate the proportion of stroke patients with a problematic substance use as defined by clinical screening scal...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabat, Yolaine, Sibon, Igor, Berthoz, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233374/
https://www.ncbi.nlm.nih.gov/pubmed/34172774
http://dx.doi.org/10.1038/s41598-021-92639-5
_version_ 1783713838053457920
author Rabat, Yolaine
Sibon, Igor
Berthoz, Sylvie
author_facet Rabat, Yolaine
Sibon, Igor
Berthoz, Sylvie
author_sort Rabat, Yolaine
collection PubMed
description The prevalence of clinically defined problematic substance use among stroke patients is overlooked and its association with post-stroke depression (PSD) is unknown. Our aims were to: (1) estimate the proportion of stroke patients with a problematic substance use as defined by clinical screening scales; (2) determine the proportion of PSD at three months of follow-up; (3) explore if the baseline severity in substance use and its evolution are independent predictors of PSD. A cohort of first-ever non-severe stroke adult patients was screened at baseline and three months post-stroke using recommended cut-off scores of standardized scales for tobacco, alcohol and cannabis abuse. PSD was defined using the Center of Epidemiological Studies Depression scale score. Out of the 244 eligible patients, 74 (30.3%) presented a problematic substance use, including 21 (8.6%) polydrug abusers. Among these patients, the prevalence of PSD was 50.8%, including 29.5% of severe depression. The severity of tobacco dependence at baseline was found to double the risk (OR 1.59, 95% CI 1.05–2.43) of presenting a PSD, independently of previously reported risk factors. We found no significant evidence for an effect of the evolution in substance use at follow-up. Addictive disorders are part of the critical unmet needs that should be addressed in the management of PSD.
format Online
Article
Text
id pubmed-8233374
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82333742021-07-06 Implication of problematic substance use in poststroke depression: an hospital-based study Rabat, Yolaine Sibon, Igor Berthoz, Sylvie Sci Rep Article The prevalence of clinically defined problematic substance use among stroke patients is overlooked and its association with post-stroke depression (PSD) is unknown. Our aims were to: (1) estimate the proportion of stroke patients with a problematic substance use as defined by clinical screening scales; (2) determine the proportion of PSD at three months of follow-up; (3) explore if the baseline severity in substance use and its evolution are independent predictors of PSD. A cohort of first-ever non-severe stroke adult patients was screened at baseline and three months post-stroke using recommended cut-off scores of standardized scales for tobacco, alcohol and cannabis abuse. PSD was defined using the Center of Epidemiological Studies Depression scale score. Out of the 244 eligible patients, 74 (30.3%) presented a problematic substance use, including 21 (8.6%) polydrug abusers. Among these patients, the prevalence of PSD was 50.8%, including 29.5% of severe depression. The severity of tobacco dependence at baseline was found to double the risk (OR 1.59, 95% CI 1.05–2.43) of presenting a PSD, independently of previously reported risk factors. We found no significant evidence for an effect of the evolution in substance use at follow-up. Addictive disorders are part of the critical unmet needs that should be addressed in the management of PSD. Nature Publishing Group UK 2021-06-25 /pmc/articles/PMC8233374/ /pubmed/34172774 http://dx.doi.org/10.1038/s41598-021-92639-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Rabat, Yolaine
Sibon, Igor
Berthoz, Sylvie
Implication of problematic substance use in poststroke depression: an hospital-based study
title Implication of problematic substance use in poststroke depression: an hospital-based study
title_full Implication of problematic substance use in poststroke depression: an hospital-based study
title_fullStr Implication of problematic substance use in poststroke depression: an hospital-based study
title_full_unstemmed Implication of problematic substance use in poststroke depression: an hospital-based study
title_short Implication of problematic substance use in poststroke depression: an hospital-based study
title_sort implication of problematic substance use in poststroke depression: an hospital-based study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233374/
https://www.ncbi.nlm.nih.gov/pubmed/34172774
http://dx.doi.org/10.1038/s41598-021-92639-5
work_keys_str_mv AT rabatyolaine implicationofproblematicsubstanceuseinpoststrokedepressionanhospitalbasedstudy
AT sibonigor implicationofproblematicsubstanceuseinpoststrokedepressionanhospitalbasedstudy
AT berthozsylvie implicationofproblematicsubstanceuseinpoststrokedepressionanhospitalbasedstudy